Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints

Rheumatology (Oxford). 2021 Oct 19;60(Suppl 4):iv16-iv27. doi: 10.1093/rheumatology/keab385.

Abstract

Several lines of evidence point towards the central role of IL-23 as a crucial inflammatory mediator in the pathogenesis of SpA-a group of inflammatory arthritic diseases whose symptoms span the skin, gastrointestinal tract and joints. While therapeutic blockade of IL-23 proved successful in the treatment of IBD, psoriatic skin disease and peripheral SpA, it failed in patients suffering from SpA with predominantly axial involvement. Here we review state-of-the-art discoveries on IL-23 signalling pathways across target tissues involved in SpA. We discuss the discrepancies in resident IL-23-responding cells and their downstream activities across skin, gut and joint that shape the unique immunological landscape of SpA.

Keywords: inflammatory bowel disease; interleukin 23; psoriasis; spondyloarthritis.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacterial Translocation
  • Humans
  • Interleukin-23 / physiology*
  • Joints / immunology
  • Psoriasis / etiology
  • Receptors, Interleukin / metabolism
  • Skin / metabolism
  • Spondylarthritis / immunology*
  • Spondylarthritis / microbiology

Substances

  • IL23R protein, human
  • Interleukin-23
  • Receptors, Interleukin